LY3372689
| |
| Names | |
|---|---|
| IUPAC name
N-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| |
| |
| Properties | |
| C16H22FN5O3S | |
| Molar mass | 383.44 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
LY3372689 is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase.[1][2] Its result is to reduce formation of tau protein tangles.
A molecule containing radioactive fluorine was used with a PET scan to show that LY3372689 binds in the human brain.[3]
Eli Lilly and Company is recruiting subjects for a clinical trial.[4] Some hospitals in Australia: St Vincent's Hospital, Sydney Hornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved.[5] Results of the trial were expected by June 2024.[6] Primary completion of the study occurred on 9th July 2024, with full completion expected in August 2024. In an investor call, it was disclosed that LY3372689 missed the primary endpoint of improvement on the Integrated Alzheimer's Disease Rating Scale. The detailed results of this study are expected to be disclosed at a conference in late 2024.[7]
Chemical
[edit]The molecule contains three rings: thiazole, piperidine and oxadiazole. Other functional groups included are an ether, acetamide, and a fluoride.[8]
References
[edit]- ^ "LY3372689". www.alzforum.org.
- ^ Cheng, Steven S.; Mody, Alison C.; Woo, Christina M. (2024-11-07). "Opportunities for Therapeutic Modulation of O-GlcNAc". Chemical Reviews. doi:10.1021/acs.chemrev.4c00417. ISSN 0009-2665.
- ^ Shcherbinin, Sergey; Kielbasa, William; Dubois, Susan; Lowe, Stephen L; Phipps, Krista M; Tseng, James; Kevin, Donnelly B; Natanegara, Fanni; Warner, Susan; Dreyfus, Nicolas; Lindsay-Scott, Peter; Hawk, Mai Khanh; McDonald, Nicholas; Zhang, Xiaoyu; Gilmore, Julie A; Biglan, Kevin; Mergott, Dustin J; Russell, David; Gunn, Roger N; Constantinescu, Cristian; Nuthall, Hugh Norman; Collins, Emily C (December 2020). "Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human: Neuroimaging / evaluating treatments". Alzheimer's & Dementia. 16 (S4). doi:10.1002/alz.040558. S2CID 227501893.
- ^ "Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease". clinicaltrials.gov. 22 March 2022. Retrieved 31 March 2022.
- ^ "A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease". Retrieved 31 March 2022.
- ^ Krietsch Boerner, Leigh (25 March 2022). "Hybrid meeting divulges structures of drug candidates". Chemical & Engineering News. ISSN 0009-2347.
- ^ edge.media-server.com https://edge.media-server.com/mmc/p/3kqnwjy6/. Retrieved 2024-10-06.
{{cite web}}: Missing or empty|title=(help) - ^ Dreyfus, Nicolas Jacques Francois; Lindsay-Scott, Peter James (2 August 2018). "N-[4-Fluoro-5-[[(2S,4S)-2-Methyl-4-[(5-Methyl-1,2,4-Oxadiazol-3-Yl)methoxy]-1-Piperidyl]methyl]thiazol-2-Yl]acetamide as Oga Inhibitor". Retrieved 31 March 2022.